Logo do repositório
 
Publicação

Persistence of IgG COVID-19 antibodies: a longitudinal analysis

2023Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorCarvalho, Álvaro
dc.contributor.authorHenriques, Ana Rita
dc.contributor.authorQueirós, Paula
dc.contributor.authorRodrigues, Joana
dc.contributor.authorMendonça, Nuno
dc.contributor.authorRodrigues, Ana Maria
dc.contributor.authorCanhao, Helena
dc.contributor.authorSousa, Germano de
dc.contributor.authorAntunes, Francisco
dc.contributor.authorGuimarães, Miguel
dc.date.accessioned2025-07-31T11:14:03Z
dc.date.available2025-07-31T11:14:03Z
dc.date.issued2023
dc.description© 2023 Carvalho, Henriques, Queirós, Rodrigues, Mendonça, Rodrigues, Canhão, de Sousa, Antunes and Guimarães. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractBackground and aim: The kinetics of antibody production in response to coronavirus disease 2019 (COVID-19) infection is not well-defined yet. This study aimed to evaluate the antibody responses to SARS-CoV-2 and its dynamics during 9-months in a cohort of patients infected during the first phase of the pandemic. As a secondary aim, it was intended to evaluate the factors associated with different concentrations of IgG antibodies. Methods: A prospective cohort study was conducted from June 2020 to January 2021. This study recruited a convenience sample of adult individuals who where recently diagnosed with COVID-19 and were living in mainland Portugal. A total of 1,695 blood samples were collected from 585 recovered COVID-19 patients up to 9 months after SARS-CoV-2 acute infection. A blood sample was collected at baseline and three, 6 and 9 months after SARS-CoV-2 acute infection to assess the concentration of IgG antibody against SARS-CoV-2. Results: The positivity rate of IgG reached 77.7% in the first 3 months after symptom onset. The IgG persists at all subsequent follow-up time-points, which was 87.7 and 89.2% in the 6th and 9th months after symptom onset, respectively. Three distinct kinetics of antibody response were found within the 9 months after infection. Kinetic 1 (K1) was characterized by a constant low IgG antibody concentration kinetic (group size: 65.2%); kinetic 2 (K2), composed by constant moderate IgG kinetic (group size: 27.5%) and kinetic 3 (K3) characterized by higher IgG kinetic (group size: 7.3%). People with ≥56 years old (OR: 3.33; CI 95%: [1.64; 6.67]; p-value: 0.001) and symptomatic COVID-19 (OR: 2.08; CI 95%: [1.08; 4.00]; p-value: 0.031) had higher odds of a "Moderate IgG kinetic." No significant association were found regarding the "Higher IgG kinetic." Conclusion: Our results demonstrate a lasting anti-spike (anti-S) IgG antibody response at least 9 months after infection in the majority of patients with COVID-19. Younger participants with asymptomatic disease have lower IgG antibody positivity and possibly more susceptible to reinfection. This information contributes to expanding knowledge of SARS-CoV-2 immune response and has direct implications in the adoption of preventive strategies and public health policies.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Public Health. 2023 Jan 10:10:1069898pt_PT
dc.identifier.doi10.3389/fpubh.2022.1069898pt_PT
dc.identifier.eissn2296-2565
dc.identifier.urihttp://hdl.handle.net/10400.5/102585
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/public-healthpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectIgGpt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectAntibody responsespt_PT
dc.subjectHumoral immune responsept_PT
dc.subjectPost-infection immunitypt_PT
dc.titlePersistence of IgG COVID-19 antibodies: a longitudinal analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Public Healthpt_PT
person.familyNameCanhao
person.familyNameAntunes
person.givenNameHelena
person.givenNameFrancisco
person.identifier.orcid0000-0002-3239-2809
person.identifier.orcid0000-0001-7932-1154
person.identifier.scopus-author-id6602393492
person.identifier.scopus-author-id7006648941
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication48f3be39-37f9-44de-9c7e-22e49a89efe5
relation.isAuthorOfPublicationa28493a5-9101-4173-8863-74ee946d6ced
relation.isAuthorOfPublication.latestForDiscovery48f3be39-37f9-44de-9c7e-22e49a89efe5

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Persistence_IgG.pdf
Tamanho:
1.27 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-ISAMB-Artigos em Revistas Internacionais